Behring

Hemgenix—developed by the pharmaceutical company CSL Behring, based in King of Prussia, Pennsylvania—uses a modified virus to deliver a gene to the recipient’s liver cells.

Biopharmaceutical firm CSL Behring manufactures the gene therapy treatment Hemgenix, which allows patients with hemophilia to produce a protein that makes their blood clot in open wounds and halt prolonged bleeding.

Drugmaker CSL Behring announced the $3.5 million price tag shortly after the FDA approval, saying its drug would ultimately reduce health care costs because patients would have fewer bleeding incidents and need fewer clotting treatments.

The low point: There might be no lower point in team history than Aug. 30, 1988, the date when Ken Behring bought the team from the Nordstrom family.

That clause was included in Referendum 48, which was passed in 1997 and funded the construction of Lumen Field, which was a condition of Paul Allen’s purchase of the team from Ken Behring.